UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1428279 (State or ot ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q4 2022 Results Conference Call September 23, 2022 1:00 PM ET Company Participants Colin Clancy - VP, IR Eric Adams - President and CEO Michael Woudenberg - COO Brenda Edwards - Interim CFO Dr. Eric Hsu - SVP, Preclinical Research and Development Conference Call Participants Scott Henry - ROTH Capital Partners Raghuram Selvaraju - H.C. Wainwright Operator Good day. And thank you for standing by. Welcome to InMed Pharmaceuticals Fourth Quarter Fiscal 2022 Financial Res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98- ...

Corporate Presentation MARCH 2022 :INM www.inmedpharma.com : INM 2 Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") including, among others, statements concerning: unlocking the full potential of cannabinoid pharmaceuticals; anticipated development activities, timelines, catalysts, and milestones; the potential benefits of product candidates; anticipat ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q2 2022 Earnings Conference Call February 15, 2022 2:00 PM ET Corporate Participants Colin Clancy - Senior Director of Investor Relations Eric Adams - President and Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs Shane Johnson - Senior Vice President and General Manager of BayMedica Conference Call Participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q4 2021 Earnings Conference Call September 24, 2021 11:00 AM ET Company Participants Colin Clancy - Senior Director of Investor Relations Eric Adams - President and Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control Conference Call Partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 8 ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q3 2021 Earnings Conference Call May 13, 2021 11:00 AM ET Company Participants Bruce Colwill - Chief Financial Officer Eric Adams - President and Chief Executive Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control Conference Call Participants Scott Henry - ROTH Capital Markets Operator Good morn ...